Clinical Trial Update: PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring PD-1 blockade and bevacizumab as a substitute for cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 blockade

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN